ストックスクリーナーアプリを入手
16.05
1.95%
-0.395
前日終値:
$16.45
開ける：
$16.53
24時間の取引高:
6.39M
Relative Volume:
0.29
時価総額：
$3.68B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
23.27
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
+3.40%
1か月 パフォーマンス:
-31.30%
6か月 パフォーマンス:
-66.68%
1年 パフォーマンス:
-60.55%
1日の値動き範囲:
$15.98
$16.84
1週間の範囲:
$14.31
$16.91
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
16.13 | 3.75B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.78 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
123.21 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.26 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.86 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
484.21 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims and Hers Expands Its Technology Driven Consumer Health Platform - Zacks Investment Research
Hims & Hers Health (HIMS) Leads as Most Shorted Stock Among Mid-to-Large Caps - GuruFocus
Locally-owned pharmacy stops stocking GLP-1 medications, calls out insurance practices - AOL.com
Hims & Hers Health Hits Major Milestones With Strategic Expansion - timothysykes.com
Hims Hers Health 59% Revenue Growth Meets Margin Pressure From Global Expansion - Smartkarma
Hims & Hers Slips as FDA Targets GLP-1 Compounders - GuruFocus
Hims & Hers Health stock: Technical indicators reflect volatility as price gains 4.14% - Traders Union
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes - FinancialContent
Hims & Hers Health (HIMS) Faces High Short Interest Amid Sector Trends - GuruFocus
CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - Insider Monkey
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last - Stocktwits
Hims & Hers (HIMS) Faces Setback as FDA Issues Warning Letters - GuruFocus
Hims & Hers down as FDA targets GLP-1 compounders (HIMS:NYSE) - Seeking Alpha
US FDA warns 30 telehealth firms over misleading ads for compounded weight‑loss drugs - Reuters
Hims & Hers Health's Options Frenzy: What You Need to Know - Benzinga
Hims & Hers Health: Leaving GLP-1s Behind (NYSE:HIMS) - Seeking Alpha
HIMS Pharmacy Partner to Relaunch Compounded Version of Wegovy - GuruFocus
Strive Pharmacy says it will not resume compounded oral semaglutide sales - Reuters
Hims & Hers Health stock price forecast: Bearish momentum persists as HIMS slides 5.34% - Traders Union
Can Hims & Hers Overcome the FDA’s GLP-1 Crackdown? - TipRanks
Hims expansion may not come in time for risky GLP-1 business - Reuters
Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze - Trefis
United StatesK&L Gates Advises Blackbird Ventures on Eucalyptus Sale to Hims & Hers Health, Inc. - Mondaq
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
HIMS: Personalized care, tech-driven growth, and global expansion fuel strong revenue and margin outlook - TradingView
Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5%Should You Buy? - MarketBeat
Hims & Hers Surges on Strong Results and Strategic Acquisitions - StocksToTrade
Why Hims & Hers Health (HIMS) Is Down 6.4% After New Shelf Filing And Regulatory Scrutiny - Yahoo Finance
What's Behind The Jump In Hims & Hers Health Stock? - Benzinga
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal
Check Out What Whales Are Doing With HIMS - Benzinga
Hims & Hers stock rises 3.93% as technical indicators show strong selling pressure - Traders Union
What is behind Hims & Hers Health recent gain in value today - Traders Union
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - AOL.com
Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances - Stocktwits
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
Hims & Hers Expands Digital Health and Global Platform Strategy - Nasdaq
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving - Yahoo Finance
Zacks Research Upgrades Hims & Hers Health (NYSE:HIMS) to "Hold" - MarketBeat
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? - Nasdaq
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making - Nasdaq
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
How Investors Are Reacting To Hims & Hers Health (HIMS) Softer GLP-1 Outlook And ESOP Share Offering - simplywall.st
Inside the Legal Battle Between Novo Nordisk and Hims & Hers - The Fashion Law
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026 - FinancialContent
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play - TechStock²
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - The Motley Fool
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
大文字化:
|
ボリューム (24 時間):